Seek Returns

EXEL vs. JNJ: Exelixis vs. Johnson & Johnson Stock Comparison

How do Exelixis (EXEL) and Johnson & Johnson (JNJ) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Exelixis (EXEL) and Johnson & Johnson (JNJ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but EXEL is classified in Biotechnology while JNJ is classified in Pharmaceuticals.

Company profile comparison for Exelixis (EXEL) and Johnson & Johnson (JNJ)
Profile ItemEXELJNJ
NameExelixis Inc.Johnson & Johnson
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyPharmaceuticals
GICS Sub-IndustryBiotechnologyPharmaceuticals
Market Capitalization16.98 billion USD664.95 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateApril 17, 2000January 2, 1962
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

EXEL
JNJ
GSPC
Loading price history…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Exelixis (EXEL) and Johnson & Johnson (JNJ). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Exelixis (EXEL) and Johnson & Johnson (JNJ). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Total Return (1Y)74.98%53.82%
Total Return (3Y, Annualized)50.33%27.51%
Total Return (5Y, Annualized)31.10%14.71%

Risk Profile

Drawdown History

EXEL
JNJ
GSPC
Loading price history…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Exelixis (EXEL) and Johnson & Johnson (JNJ). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Volatility (1Y, Annualized)34.17%21.23%
Beta (5Y)0.410.21
Max Drawdown (5Y)-35.41%-18.41%
Avg. Volume (3M)2.33M6.93M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
EXEL and JNJ are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Sharpe Ratio (1Y)2.072.33
Sortino Ratio (1Y)3.233.66

Profitability

ROE (TTM)

Both Exelixis (EXEL) at 44.32% and Johnson & Johnson (JNJ) at 20.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

44.32%

Max
109.18%
EXEL
44.32%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.02%

Max
109.18%
JNJ
20.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Exelixis (EXEL) at 35.45% keeps the most of each sales dollar — above its industry’s net margin range — and Johnson & Johnson (JNJ) at 16.20% also retains a top-quartile share.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.45%

EXEL
35.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.20%

Max
18.05%
JNJ
16.20%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Exelixis (EXEL) at 40.75% and Johnson & Johnson (JNJ) at 25.74% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

40.75%

Max
83.12%
EXEL
40.75%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.74%

Max
83.12%
JNJ
25.74%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
ROE (TTM)44.32%20.02%
ROA (TTM)23.52%8.46%
Net Margin (TTM)35.45%16.20%
Operating Margin (TTM)40.75%25.74%
Gross Margin (TTM)96.26%67.78%

Growth

Revenue Growth

Both Exelixis (EXEL) at 6.98% and Johnson & Johnson (JNJ) at 6.05% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their Revenue Growth across different time periods.

EPS Growth

Johnson & Johnson (JNJ) at 90.50% sits in the top EPS growth quartile, while Exelixis (EXEL) at 57.95% is closer to the peer norm — faster per-share earnings growth for JNJ.

Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Revenue Growth (YoY)6.98%6.05%
Revenue Growth (3Y CAGR)12.93%5.60%
EPS Growth (YoY)57.95%90.50%
EPS Growth (3Y CAGR)70.59%17.90%

Financial Strength

Current Ratio (MRQ)

Exelixis (EXEL) at 3.21 keeps current ratio within its industry’s typical mid-range, while Johnson & Johnson (JNJ) at 1.02 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JNJ.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.21

Max
25.13
Q3
12.13
Median
5.52
EXEL
3.21
Q1
2.47
Min
0.10

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.02

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
JNJ
1.02
Min
0.10
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Exelixis (EXEL) at 0.09 and Johnson & Johnson (JNJ) at 0.55 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.09

Max
1.42
Q3
0.65
Median
0.15
EXEL
0.09
Q1
0.02
Min
0.00

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.55

Max
1.42
Q3
0.65
JNJ
0.55
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Current Ratio (MRQ)3.211.02
Debt / Equity (MRQ)0.090.55
Net Debt / EBITDA-0.710.79

Dividends

Dividend Yield (TTM)

Exelixis (EXEL) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a yield of 1.94%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

JNJ
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Exelixis (EXEL) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Johnson & Johnson (JNJ) reports a payout of 80.12%, ranking against industry peers normally.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

EXEL
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

80.12%

JNJ
80.12%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
Dividend Yield (TTM)0.00%1.94%
Dividend Payout Ratio (TTM)0.00%80.12%

Valuation

P/E Ratio (TTM)

Both Exelixis (EXEL) at 20.83 and Johnson & Johnson (JNJ) at 41.92 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.83

Max
85.34
Q3
43.46
Median
26.69
EXEL
20.83
Q1
13.30
Min
0.07

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

41.92

Max
85.34
Q3
43.46
JNJ
41.92
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Exelixis (EXEL) at 6.80 and Johnson & Johnson (JNJ) at 6.69 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.80

Max
58.18
Q3
25.77
Median
7.30
EXEL
6.80
Q1
3.01
Min
0.01

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
58.18
Q3
25.77
Median
7.30
JNJ
6.69
Q1
3.01
Min
0.01
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both Exelixis (EXEL) at 9.28 and Johnson & Johnson (JNJ) at 8.16 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

EXEL

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.28

Max
13.53
EXEL
9.28
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

JNJ

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.16

Max
13.53
JNJ
8.16
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Exelixis (EXEL) vs. Johnson & Johnson (JNJ): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Exelixis (EXEL) and Johnson & Johnson (JNJ)
MetricEXELJNJ
P/E Ratio (TTM)20.8341.92
P/S Ratio (TTM)6.806.69
P/B Ratio (MRQ)9.288.16
Free Cash Flow Yield (TTM)4.47%2.78%